Phase I/II trial of amrubicin hydrochloride in 3rd line treatment for patients with recurrent non-small cell lung cancer [AMNOL-3rd]
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMNOL-3rd
- 22 Jul 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 29 May 2007 New trial record.